Bristol Myers Squibb’s growth portfolio is offsetting declines in older products as planned, even as star heart drug Camzyos faces new competition. A year ago, in the first quarter of 2025, BMS’ ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: Spacex SpaceX's ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A SpaceX Falcon Heavy rocket carrying the National Oceanic and Atmospheric Administration's ...

Falcon Cam at a Manhattan office building revealed the first peregrine falcon to hatch there in years. By James Barron Good morning. It’s Thursday. Today we’ll find out about a newborn in a closely ...

PARIS AND MERIGNAC, France—Dassault Aviation unveiled the long-awaited Falcon 10X business jet as it prepares for an intense period of flight trials to finally get the product into user hands. The ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

Jared Lindzon is the co-author of "Do More in Four: Why It’s Time for a Shorter Workweek" Courtesy Intamin Amusement Rides and Six Flags Qiddiya City The world’s tallest, fastest, and longest roller ...

Learn how to design and craft your own custom laser-cut sign using the Creality Falcon A1. This step-by-step laser tutorial will guide you through the entire process, from setup to the perfect ...

Falcons are a class of birds best known for their speed, vision and hunting prowess. Here’s the story of perhaps the most impressive falcon of all. There are over 35 recognized species of falcons, all ...

Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...